U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents

By John Kruzel

WASHINGTON (Reuters) – The U.S. Supreme Court on Thursday ruled against Amgen Inc (NASDAQ:) in its bid to revive patents on its cholesterol-lowering drug Repatha over a legal challenge by French rival Sanofi (NASDAQ:) SA.

The decision upheld a lower court’s ruling that had invalidated Amgen’s patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating the full scope of its claimed innovation.